AU2001275530A1 - Inhibitors of c-reactive protein induced inflammation - Google Patents
Inhibitors of c-reactive protein induced inflammationInfo
- Publication number
- AU2001275530A1 AU2001275530A1 AU2001275530A AU7553001A AU2001275530A1 AU 2001275530 A1 AU2001275530 A1 AU 2001275530A1 AU 2001275530 A AU2001275530 A AU 2001275530A AU 7553001 A AU7553001 A AU 7553001A AU 2001275530 A1 AU2001275530 A1 AU 2001275530A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibitors
- reactive protein
- induced inflammation
- protein induced
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010074051 C-Reactive Protein Proteins 0.000 title 1
- 102100032752 C-reactive protein Human genes 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21041500P | 2000-06-08 | 2000-06-08 | |
US60/210,415 | 2000-06-08 | ||
PCT/US2001/040941 WO2001094951A2 (en) | 2000-06-08 | 2001-06-08 | Inhibitors of c-reactive protein induced inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001275530A1 true AU2001275530A1 (en) | 2001-12-17 |
Family
ID=22782810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001275530A Abandoned AU2001275530A1 (en) | 2000-06-08 | 2001-06-08 | Inhibitors of c-reactive protein induced inflammation |
Country Status (5)
Country | Link |
---|---|
US (1) | US6764826B2 (en) |
JP (1) | JP2003536075A (en) |
AU (1) | AU2001275530A1 (en) |
CA (1) | CA2411139A1 (en) |
WO (1) | WO2001094951A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7390795B2 (en) | 2000-12-18 | 2008-06-24 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
US6964950B2 (en) * | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US7425545B2 (en) * | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
EP1470240A4 (en) * | 2002-02-01 | 2006-08-30 | Millennium Pharm Inc | Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747,1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165,2 |
GB0211136D0 (en) * | 2002-05-15 | 2002-06-26 | Univ London | Treatment and prevention of tissue damage |
US20040106584A1 (en) * | 2002-09-27 | 2004-06-03 | Linda Arterburn | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
US20050123602A1 (en) * | 2003-09-25 | 2005-06-09 | Michaelis Arthur F. | Rifalazil formulations |
WO2005056044A1 (en) * | 2003-10-23 | 2005-06-23 | Terry Du Clos | Use of c-reactive protein to treat immune complex-mediated renal disease |
WO2005058359A2 (en) * | 2003-12-15 | 2005-06-30 | Theralogic Gmbh & Co. Kg | Method for neutralizing effects of crp for increasing immune reactions to hiv |
EP1713462A1 (en) * | 2004-01-21 | 2006-10-25 | Medvet Science Pty. Ltd. | A method of modulating pro-inflammatory and inflammatory activity mediated by c-reactive protein |
US20060020043A1 (en) * | 2004-07-26 | 2006-01-26 | Roger Berlin | Methods and compositions for reducing C-reactive protein |
WO2006066599A2 (en) * | 2004-12-22 | 2006-06-29 | Rheoscience A/S | Mas related g protein coupled receptors as drug targets |
US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
EP2386858B1 (en) | 2006-04-04 | 2015-07-15 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
US7642062B2 (en) * | 2006-12-29 | 2010-01-05 | Avon Products Inc. | Compositions and methods of their use for improving the condition and appearance of skin |
WO2008089482A1 (en) * | 2007-01-20 | 2008-07-24 | Boehringer Ingelheim International Gmbh | C-reactive protein (crp) knockout mouse |
JP5678045B2 (en) | 2009-06-08 | 2015-02-25 | シンギュレックス・インコーポレイテッド | High sensitivity biomarker panel |
WO2011119722A2 (en) * | 2010-03-23 | 2011-09-29 | Rock Creek Pharmaceuticals, Inc. | Use of anatabine to treat inflammation and methods of synthesizing anatabine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5221605A (en) * | 1984-10-31 | 1993-06-22 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5238808A (en) * | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
US5284760A (en) * | 1989-04-03 | 1994-02-08 | Feinstone Stephen M | Techniques for producing site-directed mutagenesis of cloned DNA |
US5500345A (en) | 1989-04-25 | 1996-03-19 | Iatron Laboratories, Inc. | Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein |
US5658772A (en) * | 1989-12-22 | 1997-08-19 | E. I. Du Pont De Nemours And Company | Site-specific recombination of DNA in plant cells |
US5220007A (en) * | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
US5149797A (en) * | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
CA2079802C (en) * | 1990-04-05 | 2001-09-18 | Roberto Crea | Walk-through mutagenesis |
US5380721A (en) * | 1990-09-10 | 1995-01-10 | Sterling Winthrop Inc. | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents |
ES2086805T3 (en) * | 1992-04-12 | 1996-07-01 | Elpatronic Ag | PROCEDURE AND DEVICE FOR WELDING SHEETS TO FORM RIMS BY LASER BEAM. |
US5389514A (en) * | 1992-08-28 | 1995-02-14 | Fox Chase Cancer Center | Method for specifically altering the nucleotide sequence of RNA |
US5527695A (en) * | 1993-01-29 | 1996-06-18 | Purdue Research Foundation | Controlled modification of eukaryotic genomes |
EP0765475A1 (en) | 1994-05-18 | 1997-04-02 | Ligand Pharmaceuticals, Inc. | Screening for cytokine modulators |
US5789166A (en) * | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
EP0931263A1 (en) * | 1996-09-06 | 1999-07-28 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Method of screening for side effects of anticonceptives or estrogen and/or progesterone replacements or supplements |
US6190670B1 (en) * | 1999-04-12 | 2001-02-20 | Immtech International Inc. | Use of mCRP to enhance immune responses |
-
2001
- 2001-06-08 CA CA002411139A patent/CA2411139A1/en not_active Abandoned
- 2001-06-08 JP JP2002502449A patent/JP2003536075A/en not_active Withdrawn
- 2001-06-08 WO PCT/US2001/040941 patent/WO2001094951A2/en not_active Application Discontinuation
- 2001-06-08 AU AU2001275530A patent/AU2001275530A1/en not_active Abandoned
- 2001-06-08 US US09/878,124 patent/US6764826B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2001094951A9 (en) | 2003-02-13 |
CA2411139A1 (en) | 2001-12-13 |
JP2003536075A (en) | 2003-12-02 |
WO2001094951A3 (en) | 2002-07-18 |
US6764826B2 (en) | 2004-07-20 |
US20020142283A1 (en) | 2002-10-03 |
WO2001094951A2 (en) | 2001-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002213485A1 (en) | Inhibitors of protein kinases | |
AU2001275530A1 (en) | Inhibitors of c-reactive protein induced inflammation | |
AU2001282009A1 (en) | Non-steroidal inflammation inhibitors | |
PT1438068E (en) | Antibody inhibitors of gdf-8 and uses thereof | |
AU2002316137A1 (en) | Method of determining protein interaction inhibitors | |
AU2002339348A1 (en) | Inhibition of STAT-1 | |
AU2002243402A1 (en) | Inhibitors of histone deacetylase | |
AU2001258771A1 (en) | -secretase inhibitors | |
AU2001270260A1 (en) | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | |
AU2001239791A1 (en) | Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production | |
AUPR392301A0 (en) | Protein phosphatase inhibitors | |
AU2003211093A1 (en) | Inhibitors of rgs proteins | |
AU2001247882A1 (en) | Tricyclic protein kinase inhibitors | |
AU2002230385A1 (en) | Peptide deformylase inhibitors | |
AU2576501A (en) | Protein kinase inhibitors | |
AU2002337913A1 (en) | Glycosulfopeptide inhibitors and methods of use thereof | |
AU2001293538A1 (en) | Novel protein tyrosine phosphatase inhibitor | |
AU2002338734A1 (en) | Use of phosphorodiesterase IV inhibitors | |
AU5673099A (en) | Inhibitors of amyloid formation | |
AU2002214038A1 (en) | Inhibitors of transglutaminases | |
AU2002365928A1 (en) | Inhibitors of autoinducer transporters | |
AU2003258941A1 (en) | Metalloproteinase inhibitors and intermediates for preparation thereof | |
AU2002218084A1 (en) | Inhibitors of thromboxane formation and action | |
AU2002305868A1 (en) | Inhibitors of reggamma | |
AU2002221882A1 (en) | Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors |